Badgley, Phelps & Bell’s Vertex Pharmaceuticals VRTX Stock Holding History

Badgley, Phelps & Bell’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$582K	Sell	2,885 -450	-13%	-$94.1K	0.02%	153
2021 Q1	$717K	Sell	3,335 -568	-15%	-$125K	0.03%	141
2020 Q4	$922K	Hold	3,903	–	–	0.04%	134
2020 Q3	$1.06M	Buy	3,903 +765	+24%	+$211K	0.05%	119
2020 Q2	$911K	Hold	3,138	–	–	0.05%	124
2020 Q1	$747K	Sell	3,138 -6	-0.2%	-$1.38K	0.05%	118
2019 Q4	$688K	Sell	3,144 -37	-1%	-$7.49K	0.04%	132
2019 Q3	$539K	Buy	3,181 +21	+0.7%	+$3.71K	0.03%	138
2019 Q2	$579K	Hold	3,160	–	–	0.03%	139
2019 Q1	$581K	Hold	3,160	–	–	0.04%	139
2018 Q4	$524K	Buy	3,160 +16	+0.5%	+$2.77K	0.04%	134
2018 Q3	$606K	Hold	3,144	–	–	0.04%	133
2018 Q2	$534K	Hold	3,144	–	–	0.03%	136
2018 Q1	$512K	Sell	3,144 -400	-11%	-$65.3K	0.03%	137
2017 Q4	$531K	Buy	+3,544	New	+$525K	0.04%	137

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Badgley, Phelps & Bell's VRTX Position: Q2 2021 in Review

Badgley, Phelps & Bell reduced its Vertex Pharmaceuticals (VRTX) stake by 13% in Q2 2021, selling an estimated $94.1K and leaving 2,885 shares worth $582K. The position accounts for 0.02% of the portfolio, ranked #153.

Badgley, Phelps & Bell first reported a position in VRTX in Q4 2017 and has held it in 15 quarters since. The position peaked at $1.06M in Q3 2020. 976 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

Badgley, Phelps & Bell held 2,885 shares of Vertex Pharmaceuticals worth $582K as of Q2 2021.
Badgley, Phelps & Bell sold 450 Vertex Pharmaceuticals shares in Q2 2021, an estimated $94.1K.
Vertex Pharmaceuticals made up 0.02% of Badgley, Phelps & Bell's portfolio in Q2 2021, its #153 holding.
Badgley, Phelps & Bell first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 15 quarters since.
Badgley, Phelps & Bell's Vertex Pharmaceuticals position peaked at $1.06M in Q3 2020.
976 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Badgley, Phelps & Bell's 13F filing for Q2 2021, filed 28 Jul 2021.